J&J’s Tecvayli/Darzalex nod is the second under a new priority voucher scheme.
ApexOnco Front Page
Recent articles
Replimune gets a second chance, while Sarclisa could go subcutaneous.
After Aktis's $318m flotation Eikon is a bigger proposition.
Readout of the Pivot-006 trial is brought forward by nearly a year.
Prexasertib data worsen again, and biomarkers are up in the air.
$650m buys the group rights to RemeGen’s RC148.
Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
